None
EN
Pathos AI, Alphamab in $2B+ deal for TROP2/HER3 ADC
[]
BioWorld
Pfizer remains “confident in the years ahead,” CEO Albert Bourla said, pointing to investments in oncology, obesity and migraine to power the company’s next phase...